The FDA stated that efficacy was not demonstrated for PTC Therapeutics, prompting research notes from RBC Capital.
2 reports, 2 independent
Updated Aug 20
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA stated that efficacy was not demonstrated for PTC Therapeutics, prompting research notes from RBC Capital.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
PTC Therapeutics
pharmaceutical company
Nothing else this week.
Related events
- FDA failed to update warning labels despite confirmed risks associated with a product.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
- The FDA is a U.S. government agency, a basic descriptive fact about the regulator.
Coverage
Newest first; wire copies grouped- TipRanksPTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital PTC Therapeutics (PTCT) on Tuesday announced that they received a complete response letter for vatiquinone in Friedreich’s
- BioPharma DivePTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPha